Newly diagnosed Parkinson’s study for early disease
Part of Brain & nervous system clinical trials.
This study looks at people newly diagnosed with Parkinson’s disease, before starting Parkinson’s medicines, to better understand early illness. It may help researchers identify patterns that could guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Parkinson’s disease using the study’s Parkinson’s diagnostic criteria
- Your Parkinson’s symptoms have been present for 2 years or less
- Your Parkinson’s severity is mild (Hoehn-Yahr stage 2 or less)
- You are between 30 and 75 years old
- You have not started any Parkinson’s medicines yet
- You can read, understand, and sign written informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking to improve how Parkinson’s and related brain conditions are identified and treated sooner. You may be asked to share your health information and provide blood or other samples, and possibly have procedures like a spinal fluid test or a small skin sample.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This study follows people with Parkinson’s disease, certain Parkinson-like conditions, and some people at higher risk. It helps researchers learn how these illnesses start and progress, which may lead to better earlier detection and care.
This trial uses new technology (like sensors or apps) to help diagnose and monitor Parkinson's disease early. Researchers want to see if a simple, widespread healthcare service model can improve care. Both people with Parkinson's and healthy volunteers are needed.
This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.
This is an observational study, meaning it doesn’t test a new drug—researchers mainly follow people to better understand moderate Parkinson’s disease and who may be good candidates for future cell therapy. If you have moderate symptoms that aren’t well controlled with tablets, this study may help inform better future treatments.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.